ALB and cancer: PFT-HSA-TFT-Cy7 and PFT-Hcy-HSA-Cy7 showed 2.8-fold and 1.9-fold at 5 μM of concentration, in the glycation animal model (Figure 6(b)), while the treatment group of the cancer tissue with PFT-HSA-TFT-Cy7 and PFT-Hcy-HSA-Cy7 showed a decrease in the level of NFκB mRNA, with an average decrease in fold change as 2.2-fold and 2.7-fold at 1 μM and 1.6-fold and 1.5-fold at 3 μM concentration of nanoassemblies (Figure 6(a)).